Department of Biomedical Sciences School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Penn Vet Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Vet Comp Oncol. 2020 Dec;18(4):796-803. doi: 10.1111/vco.12619. Epub 2020 Jun 18.
Metastatic disease represents a serious and often fatal development in patients with solid tumours, including women with breast cancer and dogs with mammary tumours. Therefore, preventing and treating metastatic disease has remained a priority in cancer research. Desmopressin, a synthetic derivative of vasopressin, traditionally used to treat patients with bleeding disorders, has been proposed as a potential anti-metastatic agent due to its effect on haemostasis as well as multiple other anti-proliferative and anti-angiogenic mechanisms. The purpose of this study was to retest desmopressin in dogs with mammary carcinomas. A prospective randomized study was performed. Twenty-four dogs with mammary carcinomas were enrolled; 12 dogs received perioperative desmopressin and 12 received placebo. All dogs underwent standard pre-surgical staging followed by complete resection of all tumours. Intact dogs were spayed. All tumours were graded and classified according to the published guidelines. Follow-up was performed every 4 months the first year and every 6 months thereafter. Necropsies were requested on all dogs. There was no difference in time to primary metastasis or survival between desmopressin treated dogs and the placebo arm (P = .43 and .73, respectively). The distribution of negative prognostic factors, including tumour grade, stage, and high vs low bioscore (refined flexible bioscoring) category between arms was not statistically different, even though more dogs in the placebo arm had grade 3 tumours and high bioscores. Based on the results of this study, perioperative desmopressin does not prevent metastasis in dogs with mammary carcinomas.
转移性疾病是实体瘤患者（包括乳腺癌女性患者和乳腺肿瘤犬）严重且常致命的发展。因此，预防和治疗转移性疾病一直是癌症研究的重点。去氨加压素是血管加压素的合成衍生物，传统上用于治疗出血性疾病患者，由于其对止血以及其他多种抗增殖和抗血管生成机制的影响，被提议作为一种潜在的抗转移药物。本研究旨在重新测试去氨加压素在患有乳腺癌的犬中的效果。进行了一项前瞻性随机研究。纳入了 24 只患有乳腺癌的犬；其中 12 只犬接受围手术期去氨加压素治疗，12 只犬接受安慰剂治疗。所有犬均接受标准术前分期，然后切除所有肿瘤。完整的犬只接受了绝育手术。所有肿瘤均根据已发表的指南进行分级和分类。第一年每 4 个月进行一次随访，此后每 6 个月进行一次。要求所有犬进行尸检。在原发性转移或生存时间方面，去氨加压素治疗犬与安慰剂组之间没有差异（P =.43 和.73）。即使安慰剂组中更多的犬患有 3 级肿瘤和高生物评分，臂之间的负预后因素（包括肿瘤分级、分期和高与低生物评分（改良灵活生物评分）类别）分布没有统计学差异。基于这项研究的结果，围手术期去氨加压素不能预防乳腺肿瘤犬的转移。
